Santhera Pharmaceuticals Holding AG (SPHDF)

Market Cap	313.72M +43.8%
Revenue (ttm)	97.34M +97.3%
Net Income	-62.09M
EPS	-4.77
Shares Out	n/a
PE Ratio	n/a
Forward PE	193.29
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	1,189
Open	23.25
Previous Close	23.25
Day's Range	23.25 - 23.25
52-Week Range	12.28 - 23.25
Beta	-0.34
RSI	61.49
Earnings Date	Apr 28, 2026

About SPHDF

Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and sells medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the Europe, North America, and Asia. The company’s lead pipeline candidate includes Vamorolone, which is developed for the treatments of Duchenne muscular dystrophy. Its clinical stage pipeline also comprises Lonodelestat for the treatment of cystic fibrosis and other neutrophilic pulmonary diseases. Santhera Pharmaceuticals Holding AG ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2004
• Employees: 94
• Stock Exchange: OTCMKTS
• Ticker Symbol: SPHDF

Financial Performance

In 2025, SPHDF's revenue was 77.19 million, an increase of 97.32% compared to the previous year's 39.12 million. Losses were -49.24 million, 17.3% more than in 2024.

Financial numbers in CHF